Recently, because ICIs alone have shown limited efficacy in patients with CRC, combinations of ICIs with other agents, such as anti-PD-L1 antibodies or chemotherapy, are being tested in patients with CRC in clinical studies (10); however, applied combination therapies have several adverse effects, including toxicity, resistance, and side effects (3). This evidence concerns the gene CD274 and colorectal carcinoma.